not able use viral vehicle says elizabeth mcnally geneticist cardiologist directs center genetic medicine northwestern university body develop neutralizing antibodies lot questions viral delivery piece says mcnally scientific advisory board olson spin company trying commercialize duchenne technology not involved study sole duchenne treatment currently approved u.s. market injectable drug sarepta therapeutics requires continuous delivery increases dystrophin levels 1 percent approach clinical benefit differs olson works rna molecule dna eventually transcribed leaves abnormal dna sequence unchanged duchenne researcher amy wagers professor stem cell biology regenerative medicine harvard university not involved developing therapy says approaches potentially tandem help boost dystrophin think exciting